一、担保情况概述 晨光生物科技集团股份有限公司（简称"公司"）于 2025 年 4 月 3 日召开 第五届董事会第十五次会议、2025 年 5 月 6 日召开 2024 年年度股东大会，审议 通过了《关于公司与子公司或子公司之间融资担保的议案》，同意公司及合并报 表范围内各级子公司在2024年年度股东大会审议通过之日起至2025年年度股东 大会召开日，向融资机构申请办理各类融资业务余额不超 70 亿元；融资担保方 式涉及公司合并报表范围内各主体之间担保：公司向合并报表范围内各级子公司 或各级子公司之间融资担保余额不超过 25 亿元，其中：向子公司新疆晨光生物 科技股份有限公司（简称"新疆晨光"）及其合并报表范围内子公司提供担保的 余额不超过 20.5 亿元（含新疆晨光合并报表范围内各主体互相担保），向其他 子公司提供担保或其他子公司之间互相担保的余额不超过 4.5 亿元。公司股东大 会授权管理层在融资担保余额不超过 25 亿元的前提下，结合合并报表范围内各 子公司资产负债率、融资授信及放款等情况，具体调整被担保的子公司及对其担 保额度(相关文件已于 2025 年 4 月 8 日、2025 年 5 月 6 日公 ...

Summary of the Conference Call for Morning Bio Company Overview - **Company**: Morning Bio (晨光生物) - **Industry**: Plant Extracts and Natural Colorants Key Points and Arguments Industry and Market Dynamics - The prices of plant extract raw materials and products have rapidly declined over the past two years due to an expansion in upstream supply [2][3] - The company has increased raw material procurement and low-cost reserves to cope with the situation, resulting in sufficient raw material reserves for the upcoming year [2][3] - The pricing strategy is based on cost-plus, with procurement costs in 2025 expected to remain stable compared to 2024, leading to stable selling prices [4][5] - The company aims to maintain lower prices to facilitate the exit of outdated industry capacity, with potential price increases anticipated if planting areas decrease [5] Product Performance and Profitability - Major profit sources include Capsicum Red, Capsicum Extract, and Lutein, with expectations for average prices in 2026 to be higher than in 2025 [6] - The market for Lutein is gradually improving, with a forecasted gross margin recovery to around 15% for feed-grade Lutein and 30%-40% for food-grade Lutein in 2026 [9] - The competition in the Lutein market has eased, leading to improved gross margins and net profits expected to continue into the next year [6][7] Supply and Demand Trends - The supply-demand relationship for Lutein is improving but has not yet reversed the oversupply situation [8] - A few global companies dominate the supply, making aggressive price competition less meaningful [8] - Rising domestic planting costs are expected to tighten supply, leading to significantly higher prices over the next 3-5 years [8] Growth of Other Products - Other tiered products such as Silymarin, Turmeric, and Tomato Lycopene are expected to see good growth, with profitability higher than the main products [10][12] - The company anticipates that the structural changes in tiered products will lead to profit growth outpacing revenue growth [12] Business Stability and Risk Management - The company is focused on stabilizing its cottonseed business by locking in profits through strategic procurement and risk management [13] - The management emphasizes avoiding excessive procurement or risky contracts to maintain stability [13] Regulatory and Competitive Landscape - There are no recent updates on the FDA's policies regarding natural colorant replacements, which remain a point of interest [14] - The transition from synthetic to natural colorants is expected to take time, with large-scale applications not anticipated until 2027 [15] Future Outlook - The health supplement business has seen rapid growth, with new production lines expected to increase capacity by 50% [18] - The company aims to enhance production efficiency and product development over the next 3-5 years, with initial lower margins expected to improve over time [18] - Revenue and profit expectations for 2026 are optimistic, driven by price stabilization and volume growth [19] Additional Important Insights - The company holds a significant advantage in the natural colorant market, being the largest producer in China, particularly in red and yellow pigments [16][17] - The potential market for natural colorants is substantial, with a projected demand increase of 200,000 tons, translating to a market size of approximately $2-3 billion [17]

Core Insights - The food and beverage ETF Tianhong (159736) has seen significant trading activity, with a total transaction volume of 26.84 million yuan as of December 15, 2025, and a 0.87% increase in the tracked CSI Food and Beverage Index [1] - The agricultural ETF Tianhong (512620) recorded a turnover of 6.55% and a transaction volume of 21.58 million yuan, with the CSI Agricultural Theme Index rising by 0.67% [1] Group 1: Food and Beverage Sector - The food and beverage ETF Tianhong (159736) has experienced a net inflow of funds for four consecutive days, totaling 42.82 million yuan, with a peak single-day inflow of 19.36 million yuan [1][2] - Key stocks in the food and beverage ETF include leading brands in high-end and mid-range liquor, as well as beverages, dairy, and condiments, with top ten weighted stocks including Moutai, Wuliangye, and Yili [2] - The performance of constituent stocks such as Huanlejia (300997) and Yiyuan Health (605388) has been notable, with increases of 19.98% and 10.04% respectively [1] Group 2: Agricultural Sector - The agricultural ETF Tianhong (512620) has also seen a net inflow of 42.82 million yuan over the past five trading days, indicating strong investor interest [2] - The agricultural ETF tracks the CSI Agricultural Index, selecting 50 stocks with a focus on livestock (41.9%) and agricultural chemicals (17.7%), featuring leading companies like Muyuan and Haida [2] - The agricultural sector is diversifying its portfolio to mitigate cyclical risks, showcasing a strategic approach to investment [2] Group 3: Market Trends and Insights - A recent article emphasizes the importance of expanding domestic demand as a strategic move for economic stability and security, highlighting the need for sustained economic growth [4] - Research breakthroughs in barley seed dormancy mechanisms may provide new pathways for sustainable agricultural systems, addressing future food security challenges [5] - Analysts from China Galaxy Securities note a slight pullback in the food and beverage index due to seasonal sales fluctuations, but maintain a positive outlook for new consumption trends and potential recovery in traditional consumption [6]

食品饮料板块15日盘中强势拉升，乳业股表现亮眼，截至发稿，欢乐家、皇氏集团、阳光乳业等涨停， 骑士乳业涨超8%，贝因美、晨光生物涨约5%。 消息面上，12月13日，全国医疗保障工作会议在北京召开，国家医保局在会议上发布多项数据和措施， 其中包括，力争2026年全国基本实现政策范围内分娩个人"无自付" 。 2026年，医保部门将推动将灵活就业人员、农民工、新就业形态人员纳入生育保险覆盖范围。合理提升 产前检查医疗费用保障水平，力争全国基本实现政策范围内分娩个人"无自付"。将适宜的分娩镇痛项目 按程序纳入基金支付范围。全面实现生育津贴按程序直接发放给参保人。 开源证券近日指出，近年婴配粉行业需求承压，政策刺激下需求及消费信心有望恢复。从整体乳制品行 业来看，长期也将受益于政策刺激下人口问题改善趋势。此外，近期乳制品行业出现新的积极变化，一 是国内乳企开始利用奶价底部窗口期发展以乳清为代表的深加工产品，产能逐渐释放后有望加大原奶下 游需求，将进一步填补供需缺口；二是行业开始探索出口潜力，当前国内大包粉价格优势明显，乳企在 确保相关指标及生产规范性的前提下尝试出口；两者均带来行业需求新动能，叠加供给侧持续出清，行 业 ...

Core Viewpoint - The A-share market's industrial hemp concept stocks have shown strong performance, with notable gains in several companies, driven by potential regulatory changes in the U.S. regarding cannabis classification [1][2]. Company Performance - Shunhao Co., Ltd. (002565) reached a limit-up with a 10% increase, total market value at 16.9 billion [2]. - Fuan Pharmaceutical (300194) rose by 4.91%, with a market cap of 5.592 billion [2]. - Blue Sky Technology (300487) increased by 4.85%, total market value at 29.1 billion [2]. - Jinying Co., Ltd. (600232) saw a 4.10% rise, with a market cap of 2.593 billion [2]. - Chengyitong (300430) grew by 3.82%, total market value at 5.117 billion [2]. - Yongji Co., Ltd. (603058) increased by 3.44%, with a market cap of 3.740 billion [2]. - Morning Light Biology (300138) rose by 3.19%, total market value at 6.097 billion [2]. Regulatory Impact - Reports indicate that former President Trump is expected to instruct the government to reclassify cannabis as a lower-risk substance, which could represent a significant shift in U.S. cannabis policy [1][2]. - Discussions have taken place between Trump and industry executives, as well as health officials, regarding this potential reclassification [2]. - The reclassification could facilitate easier buying and selling of cannabis, addressing tax burdens and banking service obstacles for cannabis businesses [2].

Core Insights - The company reported significant profit growth in Q3 2025, with a net profit of 0.89 billion yuan, a year-on-year increase of 338.7% [1] - The company's revenue for the first three quarters of 2025 was 50.5 billion yuan, a decrease of 3.4% year-on-year, while the net profit reached 3.0 billion yuan, up 385.3% [1] Revenue and Profitability - In Q3 2025, the company achieved total revenue of 13.90 billion yuan, a decline of 19.9% year-on-year, but the net profit showed a substantial increase [1] - The gross profit margin for the plant extraction business was 20.86%, up 4.91 percentage points year-on-year, while the cottonseed business gross margin was 7.20%, an increase of 8.05 percentage points [1] - The company’s Q3 gross margin was approximately 16%, a significant increase of 10.6 percentage points year-on-year [2] Business Segment Performance - The plant extraction business generated revenue of 24.99 billion yuan in the first three quarters, a year-on-year increase of 7.35%, with a gross margin of 20.86% [1] - The cottonseed business reported revenue of 23.53 billion yuan, a decline of 10.54% year-on-year, but the gross margin improved to 7.20% [1] - Sales of various products in the plant extraction segment reached historical highs, with chili red pigment sales up 36% and chili essence sales up 87% year-on-year [1] Cost and Expense Management - In Q3, the company’s selling, administrative, and R&D expense ratios were 1.4%, 3.4%, and 3.4%, respectively, with increases in each category compared to the previous year [2] - The increase in selling expenses was primarily due to the recovery of the cottonseed business, leading to higher compensation for sales staff [2] Future Outlook - The company is positioned as a leader in the domestic plant extraction industry, with significant growth potential in both domestic and international markets [2] - Revenue projections for 2025-2027 are 70.1 billion yuan, 74.8 billion yuan, and 79.6 billion yuan, with net profits expected to be 3.74 billion yuan, 4.06 billion yuan, and 4.41 billion yuan, respectively [2]

Group 1 - The core point of the article is that Chenguang Biotech has received patent and trademark certifications from the National Intellectual Property Administration and the European Patent Office for its innovative products [1] - Chenguang Biotech's revenue composition for the year 2024 is entirely derived from the agricultural and sideline food processing industry, specifically plant extracts, accounting for 100% of its revenue [1] - The current market capitalization of Chenguang Biotech is reported to be 5.9 billion yuan [2]

证券代码：300138 证券简称：晨光生物 公告编号：2025—128 晨光生物科技集团股份有限公司 关于公司正式收到专利证书和商标注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"或"晨光生物"）于近 日正式收到了国家知识产权局颁发的专利证书和商标注册证，获欧洲专利管理部 门专利授权一项，具体情况如下： 二、欧洲专利管理部门专利授权情况 | 专利名称 | 专利号 | | 授权日期 | | 有效期 | | | --- | --- | --- | --- | --- | --- | --- | | 一种连续蒸馏工艺 | EP3690011 | 2025 年 | 10 月 29 | 日 | 20 | 年 | "一种连续蒸馏工艺"涉及一种挥发性精油的生产方法，本发明处理能力大， 精油得率高，余热得到利用，适于热敏性物料的蒸馏。 以上专利主要是克服现有技术中的不足，对现有工艺进行的改进和提升，除 "一种天然复配甜味剂及其制备方法"及"一种生姜提取物及其精制方法"外， 其他专利均已应用于生产。上述专利的取得，有利 ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—129 晨光生物科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 晨光生物科技集团股份有限公司（简称"公司"）于 2025 年 4 月 3 日召开 第五届董事会第十五次会议、2025 年 5 月 6 日召开 2024 年年度股东大会，审议 通过了《关于公司与子公司或子公司之间融资担保的议案》，同意公司及合并报 表范围内各级子公司在2024年年度股东大会审议通过之日起至2025年年度股东 大会召开日，向融资机构申请办理各类融资业务余额不超 70 亿元；融资担保方 式涉及公司合并报表范围内各主体之间担保：公司向合并报表范围内各级子公司 或各级子公司之间融资担保余额不超过 25 亿元，其中：向子公司新疆晨光生物 科技股份有限公司（简称"新疆晨光"）及其合并报表范围内子公司提供担保的 余额不超过 20.5 亿元（含新疆晨光合并报表范围内各主体互相担保），向其他 子公司提供担保或其他子公司之间互相担保的余额不超过 4.5 亿元。公司股东大 会授权管理层在融资担保余额不超 ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—127 晨光生物科技集团股份有限公司 关于持股 5%以上股东部分股份质押延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）近日接到持股 5%以 上股东卢庆国先生通知，获悉其所持有本公司的部分股份质押延期，具体如下： 二、股东股份累计质押的基本情况 四、备查文件 延期购回交易协议书 特此公告 晨光生物科技集团股份有限公司 截至公告披露日，上述股东及其股份权益变动一致行动人所持质押股份情况 注：上表中限售股份性质为高管锁定股；分项数值之和与合计数差异为小数项四舍五入所致。 股东名 称 是否为控股 股东或第一 大股东及其 一致行动人 本次质押 延期数量 （股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 原质押 开始日 期 原质押 到期日 延期后 质押到 期日 质权人 用途 卢庆国 是 2,982,000 3.04% 0.62% 否 2024-12 -02 2025-12 -02 2026-12 -02 国泰海 通证券 股份有 ...